Modeling CRISPR to Preserve Antibiotics
建立 CRISPR 模型以保存抗生素
基本信息
- 批准号:8503236
- 负责人:
- 金额:$ 22.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAntibiotic ResistanceAntibiotic TherapyAntibioticsAntiviral AgentsBacteriaBacteriophagesBiologyCessation of lifeComputational ScienceDataElementsEmployee StrikesEngineeringEnterococcusEnterococcus faecalisEvolutionExtinction (Psychology)FutureGenomeGenomicsGenus staphylococcusGoalsHealth Care CostsHorizontal Gene TransferHospitalsImmunityIndividualInfectionLifeMaintenanceMediatingMicrobeModelingMovementMulti-Drug ResistanceMutationNatureNosocomial InfectionsPathogenicityPathogenicity IslandPharmaceutical PreparationsPlasmidsPopulationPopulation SizesPredatory BehaviorProliferatingPublic HealthRegimenRelative (related person)Research Project GrantsResistanceRoleRunningSystemTechnologyTestingTherapeuticTimeVancomycinViralVirulenceVirusbasecommensal microbescomparative genomicscostdesigndosagefitnessinnovationpathogenpathogenic bacteriapredictive modelingpressurepreventprogramspublic health relevanceresponsetherapy designtraituptake
项目摘要
DESCRIPTION (provided by applicant): The enterococci emerged as leading causes of multidrug resistant hospital acquired infection (HAI) in the 70's and 80's. They currently rank second only to the staphylococci, causing 12.1% of all HAI. Antibiotic resistant HAI add over $ 20 Billion annually in excess health care costs. Therefore $ 2.42 Billion annually, along with ~ 12,000 deaths are ascribable to HAI caused by enterococci, making it a leading public health concern. Moreover, they are now transmitting resistance to the last line drug, vancomycin, to the staphylococci. In preliminary data, we showed that the emergence of enterococci as leading hospital pathogens coincided with the outgrowth of strains in the 70's and 80's that lacked CRISPR defense against phage, plasmid and other mobile element entry into the genome. Our comparative genomics study indicated that under intense antibiotic pressure, enterococci without CRISPR were at an advantage for acquiring antibiotic resistance determinants. They became resistant to multiple antibiotics and proliferated in hospitals. Coinciding with the loss of
CRISPR, phages lysogenized the hospital strains; and pathogenicity islands, transposons and other plasmids and mobile elements entered. As a result, hospital endemic enterococci have genomes over 25% larger than commensal strains, with a synergistic convergence of virulence traits and antibiotic resistances. In nature, most evidence indicates that phage pressure has selected for the occurrence and maintenance of the CRISPR defense over eons of evolution. However, the sudden and massive application of high levels of antibiotics in the last 50 years has selected for strains lacking that defense, with presumably enhanced ability to acquire new antibiotic resistances. In this exploratory R21 application, we propose to quantify the level of defense against plasmid and phage entry into Enterococcus faecalis accorded by the CRISPR locus, and to model using varying parameters, the tension between antibiotic selection and phage selection for the loss/maintenance of this locus. This will provide the preliminary data for a larger program to identify the optimum antibiotic use parameters for preserving CRISPR in the enterococcal population, thereby inhibiting transfer of antibiotic resistant elements, and preserving the shelf life of increasingly scarce, effective antibiotics.
描述(由申请人提供):肠球菌在70年代和80年代成为多重耐药医院获得性感染(HAI)的主要原因。它们目前仅次于葡萄球菌,占所有HAI的12.1%。抗生素耐药HAI每年增加超过200亿美元的额外医疗保健费用。因此,每年有24.2亿美元,沿着约12,000例死亡可归因于肠球菌引起的HAI,使其成为主要的公共卫生问题。此外,它们现在正在将对最后一线药物万古霉素的耐药性传递给葡萄球菌。在初步数据中,我们表明肠球菌作为主要医院病原体的出现与70年代和80年代缺乏针对噬菌体、质粒和其他移动的元件进入基因组的CRISPR防御的菌株的生长相一致。我们的比较基因组学研究表明,在强烈的抗生素压力下,没有CRISPR的肠球菌在获得抗生素耐药决定簇方面具有优势。它们对多种抗生素产生耐药性,并在医院中扩散。与失去的
CRISPR使医院菌株溶原化;致病岛、转座子和其他质粒以及移动的元件进入。因此,医院流行性肠球菌的基因组比医院菌株大25%以上,具有毒力性状和抗生素耐药性的协同收敛。在自然界中,大多数证据表明,噬菌体压力选择了CRISPR防御的发生和维持。然而,在过去的50年里,高水平抗生素的突然和大规模应用选择了缺乏这种防御的菌株,可能增强了获得新抗生素耐药性的能力。在这个探索性的R21应用中,我们建议量化CRISPR基因座对质粒和噬菌体进入粪肠球菌的防御水平,并使用不同的参数来模拟抗生素选择和噬菌体选择之间的张力,以丢失/维持该基因座。这将为一个更大的项目提供初步数据,以确定在肠球菌群体中保留CRISPR的最佳抗生素使用参数,从而抑制抗生素耐药元件的转移,并保留日益稀缺的有效抗生素的保质期。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael S Gilmore其他文献
Michael S Gilmore的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael S Gilmore', 18)}}的其他基金
The Role of Enterococcus Unique Hypothetical EF1909 in Intrinsic β-lactam Resistance
肠球菌独特的假设 EF1909 在内在 β-内酰胺耐药性中的作用
- 批准号:
10569041 - 财政年份:2022
- 资助金额:
$ 22.01万 - 项目类别:
The Role of Enterococcus Unique Hypothetical EF1909 in Intrinsic β-lactam Resistance
肠球菌独特的假设 EF1909 在内在 β-内酰胺耐药性中的作用
- 批准号:
10464409 - 财政年份:2022
- 资助金额:
$ 22.01万 - 项目类别:
New understanding of LTA as a determinant of daptomycin susceptibility in VRE E. faecium
对 LTA 作为 VRE 屎肠球菌达托霉素敏感性决定因素的新认识
- 批准号:
9926227 - 财政年份:2019
- 资助金额:
$ 22.01万 - 项目类别:
New understanding of LTA as a determinant of daptomycin susceptibility in VRE E. faecium
对 LTA 作为 VRE 屎肠球菌达托霉素敏感性决定因素的新认识
- 批准号:
9810471 - 财政年份:2019
- 资助金额:
$ 22.01万 - 项目类别:
Subproject 3 New Approaches to Treatment and Prevention of Antibiotic Resistant Infection
子项目3 治疗和预防抗生素耐药感染的新方法
- 批准号:
9151288 - 财政年份:2016
- 资助金额:
$ 22.01万 - 项目类别:
Molecular Basis for Ocular Surface Tropism in Conjunctivitis
结膜炎眼表向性的分子基础
- 批准号:
9264533 - 财政年份:2014
- 资助金额:
$ 22.01万 - 项目类别:
Molecular Basis for Ocular Surface Tropism in Conjunctivitis
结膜炎眼表向性的分子基础
- 批准号:
8670576 - 财政年份:2014
- 资助金额:
$ 22.01万 - 项目类别:
相似海外基金
Ecological and Evolutionary Drivers of Antibiotic Resistance in Patients
患者抗生素耐药性的生态和进化驱动因素
- 批准号:
EP/Y031067/1 - 财政年份:2024
- 资助金额:
$ 22.01万 - 项目类别:
Research Grant
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
- 批准号:
2307222 - 财政年份:2024
- 资助金额:
$ 22.01万 - 项目类别:
Standard Grant
Molecular Epidemiology of Antibiotic Resistance in Clostridioides difficile
艰难梭菌抗生素耐药性的分子流行病学
- 批准号:
502587 - 财政年份:2024
- 资助金额:
$ 22.01万 - 项目类别:
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
- 批准号:
2307223 - 财政年份:2024
- 资助金额:
$ 22.01万 - 项目类别:
Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 22.01万 - 项目类别:
Research Grant
Determining structural dynamics of membrane proteins in their native environment: focus on bacterial antibiotic resistance
确定膜蛋白在其天然环境中的结构动力学:关注细菌抗生素耐药性
- 批准号:
MR/X009580/1 - 财政年份:2024
- 资助金额:
$ 22.01万 - 项目类别:
Fellowship
CAREER: Systems Microbiology and InterdiscipLinary Education for Halting Environmental Antibiotic Resistance Transmission (SMILE HEART)
职业:阻止环境抗生素耐药性传播的系统微生物学和跨学科教育(SMILE HEART)
- 批准号:
2340818 - 财政年份:2024
- 资助金额:
$ 22.01万 - 项目类别:
Continuing Grant
Reinforcing the battle at the bacterial cell wall: Structure-guided characterization and inhibition of beta-lactam antibiotic resistance signalling mechanisms
加强细菌细胞壁的战斗:β-内酰胺抗生素耐药信号机制的结构引导表征和抑制
- 批准号:
480022 - 财政年份:2023
- 资助金额:
$ 22.01万 - 项目类别:
Operating Grants
The spread of antibiotic resistance in bacteria-plasmid networks
抗生素耐药性在细菌-质粒网络中的传播
- 批准号:
BB/X010473/1 - 财政年份:2023
- 资助金额:
$ 22.01万 - 项目类别:
Fellowship
An RNA Nanosensor for the Diagnosis of Antibiotic Resistance in M. Tuberculosis
用于诊断结核分枝杆菌抗生素耐药性的 RNA 纳米传感器
- 批准号:
10670613 - 财政年份:2023
- 资助金额:
$ 22.01万 - 项目类别:














{{item.name}}会员




